Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowFRA:3IP -2.35%76 EV-to-OCF is 289.10 as of Aug. 19, 2026, which is 483% above its 10-year median of 49.59. GuruFocus rates FRA:3IP with a GF Score™ of 76/100 and a GF Value™ of €35.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Harrow ranks worse than 97.91% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Harrow's Enterprise Value is €1,466.0 Mil.
Harrow's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €5.1 Mil. Therefore, Harrow's EV-to-OCF for today is 289.10.
The historical rank and industry rank for Harrow's EV-to-OCF or its related term are showing as below:
FRA:3IP'
s EV-to-OCF Range Over the Past 10 Years
Min: -546.01 Med: 49.59 Max: 15165.37
Current: 271.6
During the past 13 years, the highest EV-to-OCF of Harrow was 15165.37. The lowest was -546.01. And the median was 49.59.
FRA:3IP's EV-to-OCF is ranked worse than 97.91% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.88
vs FRA:3IP: 271.60
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-19), Harrow's stock price is €33.00.
Harrow's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.868. Therefore, Harrow's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harrow's share price for today is €33.00.
Harrow's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.868.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Harrow EV-to-OCF Related Terms
Harrow EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Harrow's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Harrow's EV-to-OCF falls into.
Harrow's current Enterprise Value is €1,466.0 Mil.
Harrow's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow (FRA:3IP) has a EV-to-OCF of 289.10 as of Aug. 19, 2026. This is 483% above median its historical median of 49.59. According to the industry distribution chart, Harrow ranks #984 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is Harrow's EV-to-OCF too high?
Harrow's current EV-to-OCF of 289.10 is 483% above median its 10-year median of 49.59. The Drug Manufacturers industry median EV-to-OCF is 10.88. Harrow's value of 289.10 is 2557.2% above this industry median. Based on the distribution chart, Harrow ranks #984 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Harrow has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's EV-to-OCF compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #984 out of 1005 companies for EV-to-OCF. This places Harrow in the lower half of its industry. The industry median EV-to-OCF is 10.88. Harrow's value of 289.10 is 2557.2% above this benchmark. While the company's 10-year median is 49.59 vs. the industry median of 10.88, Harrow has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.88, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harrow's current EV-to-OCF of 289.10 is 2557.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current EV-to-OCF is 289.10, which is 483% above median its own 10-year median of 49.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (FRA:3IP) is currently considered Fairly Valued. The stock's GF Value™ is €35.28, compared to a current price of €33.00 — trading 6.5% below its estimated fair value. The current EV-to-OCF is 289.10, which is 483% above median its 10-year median of 49.59 and 2557.2% above the Drug Manufacturers industry median of 10.88. Harrow's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Harrow (FRA:3IP), the current EV-to-OCF is 289.10 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (FRA:3IP) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of €33.00 is trading 6.5% below its estimated GF Value™ of €35.28.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for FRA:3IP:
EV-to-OCF: 289.10 (483% above median its 10-year median of 49.59)
GF Value™: €35.28 vs. price of €33.00 (6.5% below fair value)
Industry Position: 2557.2% above the Drug Manufacturers median (#984 of 1005)
No single metric tells the full story. See the FRA:3IP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
76GF Score
Get the complete analysis for FRA:3IP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3IP has been successfully added to your 
